• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    BiomX Inc. filed SEC Form 8-K: Leadership Update

    2/25/26 4:05:58 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PHGE alert in real time by email
    false 0001739174 0001739174 2026-02-19 2026-02-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    Form 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): February 19, 2026

     

    BiomX Inc.
    (Exact Name of Registrant as Specified in its Charter)

     

    Delaware   001-38762   82-3364020
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (I.R.S. Employer
    Identification No.)

     

    850 New Burton Road, Suite 201, Dover, DE   19904
    (Address of Principal Executive Offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (972) 54-561-0935

     

    n/a  
    (Former name or former address, if changed since last report)  

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.0001 par value   PHGE   NYSE American

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers. 

     

    On February 19, 2026, Alan Moses resigned from the Board of Directors (the “Board”) of BiomX Inc. (the “Company”), for personal reasons, effective immediately. Mr. Moses did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices.

     

    On February 25, 2026, the Board of the Company, pursuant to a recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Guy Arieli to serve as a Class I Director of the Company, with a term expiring at the Company’s annual meeting of stockholders in 2027, and appointed Shaked Ran to serve as a Class III Director of the Company, with a term expiring at the Company’s annual meeting of stockholders in 2026, in order to fill two existing vacancies on Company’s Board.

     

    Mr. Arieli, age 43, is a pension and investment advisory specialist with extensive experience in providing pension consulting, investment advisory, and managing strategic client portfolios for corporate and institutional clients. Since 2014, Mr. Arieli has been self-employed, providing freelance consulting services to leading insurance and financial firms, including managing El Al Airlines’ portfolio and pension arrangements for hundreds of employees. Previously, Mr. Arieli served as a Pension and Investment Advisor at Mivtach Simon Insurance Agencies Ltd. from 2012 to 2014 and as a Pension Consultant and in marketing of financial products at Perfect Investment House (a subsidiary of Altshuler Shaham) from 2009 to 2012. Mr. Arieli holds an MBA with a specialization in Finance from Netanya Academic College and a B.B.A. and Industrial Engineering degree from Ruppin Academic Center, and previously held investment advisory and pension advisory licenses issued by the Israel Securities Authority and the Capital Market, Insurance and Savings Authority, respectively.

     

    Mr. Ran, age 44, is an investment advisor and portfolio manager with over 20 years of experience (2006-present) in capital markets, financial analysis, and investment management, with expertise in market analysis, risk assessment, and developing investment strategies for private and institutional clients. Since 2015, Mr. Ran has served as a self-employed independent investment advisor and portfolio manager in Jerusalem, Israel. Previously, Mr. Ran provided portfolio management and investment advisory services on a freelance basis from 2010 to 2015, and served as a financial analyst and investment advisor from 2006 to 2010, providing market research and investment recommendations. Mr. Ran holds a certificate in Financial Markets Analysis and Investments from Capital Markets College and completed advanced coursework in Financial Information Systems at High-Tech College.

     

    There is no arrangement or understanding between Mr. Arieli or Mr. Ran and any other person pursuant to which Mr. Arieli and Mr. Ran were selected as Directors. There are no transactions, relationships or agreements between Mr. Arieli or Mr. Ran and the Company that would require disclosure pursuant to Item 404(a) of Regulation S-K promulgated under the Securities Exchange Act of 1934, as amended.

     

    The Board concluded that Mr. Arieli and Mr. Ran are qualified to serve as Directors and are independent under the rules of the NYSE American LLC. For their service as Directors, Mr. Arieli and Mr. Ran will be entitled to the compensation the Company generally provides to its Directors, with the annual cash fees prorated.

     

    In connection with her appointment, the Company will enter into an indemnification agreement with Mr. Arieli and Mr. Ran on substantially the same terms as the agreements previously entered into between the Company and each of its other Directors. The form of indemnification agreement entered into between the Company and its Directors is filed as Exhibit 10.3 to the Company’s Annual Report on Form 10-K, filed on February 19, 2026, and is incorporated herein by reference.

     

     

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      BIOMX INC.
         
    February 25, 2026 By: /s/ Jonathan Solomon
        Name:  Jonathan Solomon
        Title: Chief Executive Officer

     

    2

    Get the next $PHGE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PHGE

    DatePrice TargetRatingAnalyst
    11/16/2021$16.00 → $13.00Buy
    Chardan Capital
    10/19/2021$28.00 → $16.00Buy
    Chardan Capital
    10/18/2021$20.00 → $10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PHGE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BiomX Issues Statement Regarding Recent Common Stock Trading Activity

    NESS ZIONA, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today issued a statement in response to recent unusual market activity in its common stock. The Company is not aware of any material developments in its business or affairs that have not been previously disclosed, nor, to its knowledge, of any other reason that would account for the recent unusual market activity in its common stock. NYSE American LLC has contacted the Company in accordance with its usual practice and has advised that the Company issue this statement

    1/27/26 1:41:26 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Announces $3.0 Million Private Placement

    NESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered into definitive agreements in connection with a private investment in public equity ("Private Placement") financing for expected gross proceeds of approximately $3.0 million, before deducting placement agent fees and other offering expenses. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. About the Private PlacementIn the Private Placement, the Company agreed to issue and sell shares of its Se

    12/29/25 8:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review

    Following internal analysis and Data Monitoring Committee (DMC) feedback, the Company has elected to discontinue the BX004 Cystic Fibrosis (CF) Phase 2b trial  BiomX continues to see potential in BX011, its phage program for Staphylococcus aureus (S. aureus) infections associated with diabetic foot infections (DFI). The Company is also implementing cost cutting measures, while evaluating strategic alternatives NESS ZIONA, Israel, Dec. 08, 2025 (GLOBE NEWSWIRE) --  BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced its discontinuation of the ongoing Phase

    12/8/25 7:30:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital reiterated coverage on BiomX with a new price target

    Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $13.00 from $16.00 previously

    11/16/21 9:23:03 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chardan Capital reiterated coverage on BiomX with a new price target

    Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $16.00 from $28.00 previously

    10/19/21 8:36:54 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HC Wainwright & Co. reiterated coverage on BiomX with a new price target

    HC Wainwright & Co. reiterated coverage of BiomX with a rating of Buy and set a new price target of $10.00 from $20.00 previously

    10/18/21 12:27:44 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    SEC Filings

    View All

    BiomX Inc. filed SEC Form 8-K: Leadership Update

    8-K - BiomX Inc. (0001739174) (Filer)

    2/25/26 4:05:58 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by BiomX Inc.

    10-K - BiomX Inc. (0001739174) (Filer)

    2/19/26 11:16:52 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by BiomX Inc.

    SCHEDULE 13G/A - BiomX Inc. (0001739174) (Subject)

    2/17/26 4:47:05 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Yeganeh Reuven

    3 - BiomX Inc. (0001739174) (Issuer)

    1/16/26 7:59:12 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by *Director by Deputization Flynn James E

    4 - BiomX Inc. (0001739174) (Issuer)

    4/23/25 5:49:02 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form 4 filed by Director Merril Gregory Louis

    4/A - BiomX Inc. (0001739174) (Issuer)

    4/21/25 8:24:29 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Leadership Updates

    Live Leadership Updates

    View All

    BiomX Announces the Appointment of Susan Blum to its Board of Directors

    CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board. "We are pleased to welcome Susan Blum to our Board of Directors who joins BiomX at one of the most exciting periods in our company's history," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "For nearly two decades, Susan has held executive positions in both finance

    4/18/24 8:00:00 AM ET
    $PHGE
    $PDLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Telum Therapeutics appoints Dr. Subhendu Basu as CEO

    Dr. Basu brings over 20 years of deep technical and management expertise across academia and biotech.Dr. Basu joins the company to lead it into its next development phase, where he will focus on defining strategy, expanding the pipeline and driving corporate development.PAMPLONA, Spain and BARCELONA, Spain, March 19, 2024 /PRNewswire/ -- Telum Therapeutics ('Telum'), a pioneering biotechnology company specializing in the innovation of engineered phage endolysins as novel antibacterial agents to combat multidrug-resistant infections, is announcing the appointment of Subhendu Basu, PhD, as its new Chief Executive Officer. Dr. Basu comes to Telum with an impressive tenure of over two decades in

    3/19/24 5:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Announces the Appointment of Edward L. Williams to its Board of Directors

    CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Edward L. Williams to its Board of Directors. "We are pleased to welcome Eddie to our Board of Directors," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "As a seasoned executive with extensive board experience, Eddie has successfully led the commercialization and marketing efforts across multiple therapeutic categories for global pharmaceutical companies. His insights, advice and experience will undoubtedly hel

    10/18/23 8:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BiomX Inc.

    SC 13G/A - BiomX Inc. (0001739174) (Subject)

    11/13/24 5:14:46 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by BiomX Inc.

    SC 13G/A - BiomX Inc. (0001739174) (Subject)

    11/4/24 4:05:35 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by BiomX Inc.

    SC 13G/A - BiomX Inc. (0001739174) (Subject)

    10/28/24 4:01:32 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Financials

    Live finance-specific insights

    View All

    BiomX Announces $3.0 Million Private Placement

    NESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered into definitive agreements in connection with a private investment in public equity ("Private Placement") financing for expected gross proceeds of approximately $3.0 million, before deducting placement agent fees and other offering expenses. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. About the Private PlacementIn the Private Placement, the Company agreed to issue and sell shares of its Se

    12/29/25 8:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates

    Positive FDA feedback confirms clear clinical pathway for BX011 targeting S. aureus in Diabetic Foot Infections, building on Company's prior Phase 2 success  BiomX expects FDA feedback on BX004 clinical hold imminently; Enrollment and dosing of patients outside the U.S. are continuing in accordance with protocol Positive FDA feedback received in October provided guidance for potential Phase 3 development pathways of BX004 BiomX will host a conference call and webcast today at 8:30 AM ET NESS ZIONA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specif

    11/12/25 7:30:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX to Report Third Quarter 2025 Financial Results and Program Updates on November 12, 2025

    NESS ZIONA, Israel, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it will report its third quarter 2025 financial results and program updates before the open of the U.S. financial markets on Wednesday, November 12, 2025. The Company will host a conference call and a live audio webcast at 8:30 a.m. ET, to discuss the third quarter of 2025 financial results and provide program updates. To ensure you are connected prior to the beginning of the call, BiomX suggests registering a minimum of 5 minutes before the sta

    11/5/25 8:30:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care